Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Cracking the histone code for prostate cancer therapy

Nature Genetics volume 57, pages 2357–2358 (2025)Cite this article

Subjects

In this study, we uncover the critical role of p300/CBP-mediated histone H2B N terminus multisite lysine acetylation (H2BNTac) in defining oncogenic enhanceosomes in prostate cancer. Degradation of p300/CBP rapidly disables H2BNTac-marked oncogenic enhancers and represents a promising therapeutic strategy for enhancer-driven malignancies, including prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeting p300/CBP to disrupt H2BNTac-marked hyperactive AR enhancers in prostate cancer.

References

  1. Dai, C., Dehm, S. M. & Sharifi, N. Targeting the androgen signalling axis in prostate cancer. J. Clin. Oncol. 41, 4267–4278 (2023). A review article discussing the role of AR in prostate cancer.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Yu, X. et al. Structural insights of transcriptionally active, full-length androgen receptor coactivator complexes. Mol. Cell 79, 812–823 (2020). This paper reports the interaction between AR and p300 proteins as revealed by cryo-electron microscopy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Narita, T. et al. Acetylation of histone H2B marks active enhancers and predicts CBP/p300 target genes. Nat. Genet. 55, 679–692 (2023). This paper identifies H2BNTac as an active enhancer mark.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chen, Z. et al. Discovery of CBPD-409 as a highly potent, selective, and orally efficacious CBP/p300 PROTAC degrader for the treatment of advanced prostate cancer. J. Med. Chem. 67, 5351–5372 (2024). This paper reports the development of CBPD-409.

    Article  CAS  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Luo, J. et al. Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer. Nat. Genet. https://doi.org/10.1038/s41588-025-02336-6 (2025).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cracking the histone code for prostate cancer therapy. Nat Genet 57, 2357–2358 (2025). https://doi.org/10.1038/s41588-025-02354-4

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41588-025-02354-4

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing